<DOC>
	<DOCNO>NCT01207102</DOCNO>
	<brief_summary>Taxanes ( paclitaxel ) highly active treat breast cancer . Abraxane® ( nanoparticle albumin-bound paclitaxel ) compare standard paclitaxel improve efficacy tolerability . When combined taxane , platinum agent improve response metastatic breast cancer , carboplatin confer less toxicity cisplatin . The investigator hypothesize combination weekly Abraxane® carboplatin lengthen time progression without produce intolerable toxicity .</brief_summary>
	<brief_title>Study Of Abraxane® And Carboplatin As First-Line Treatment For Triple Negative Metastatic Breast Cancer</brief_title>
	<detailed_description>Paclitaxel cisplatin well-recognized activity treat variety tumor include breast cancer . As cytotoxin , study alone combination chemotherapeutic agent , incorporate treatment regimen woman fail previous anthracycline-based therapy . Although agent notable favorable response rate , also associate variety adverse event , may dose-limiting negative effect quality life : myelosuppression , nausea vomiting , diarrhea , stomatitis/mucositis , short- long-term neuropathy , nephrotoxicity , alopecia hypersensitivity reaction . As second-generation compound , Abraxane® carboplatin show improve response rate may mediate toxicity associate paclitaxel cisplatin , respectively . Of particular interest Abraxane 's potential reduce allergic reaction associate taxanes . This study combine two agent : primarily , evaluate progression-free survival ; secondarily , assess feasibility tolerability regimen treat poor prognosis metastatic breast cancer patient .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>Patients histologically cytologically confirm diagnosis metastatic ( Stage IV ) breast cancer ; Measurable disease accord Response Evaluation Criteria Solid Tumors ( RECIST ) ; `` Triple negative '' disease define `` tumor demonstrate expression estrogen , progesterone HER2 receptor . '' ( No expression categorize ≤ 10 % cell stain Allred ≤ 2 ) ; Aged 18 year old ; Eastern Cooperative Oncology Group ( ECOG ) ECOG/Zubrod performance status 0 1 ; life expectancy ≥ 3 month ; No prior chemotherapy metastatic disease . At least 6 month must elapse since prior adjuvant chemotherapy . Laboratory test perform within 14 day study entry showing : Granulocytes ≥ 1,500/µL ; Platelets ≥ 100,000/µL ; Hemoglobin ≥ 9.0 gm/dL ; Total bilirubin ≤ institutional upper limit normal ( ULN ) ; Aspartate transaminase ( AST ) alanine aminotransferase ( ALT ) ≤ 2.5 time ULN ; Alkaline phosphatase ≤ 5 time ULN ; Estimated creatinine clearance ≥ 60 mL/min . Urine protein : creatinine ratio ≤ 1.0. 24 hour urine protein collection demonstrate ≤ 1 gram protein per 24 hour eligible . leave ventricular ejection fraction ( LVEF ) ≥ 50 % multiple gated acquisition scan ( MUGA ) /Echocardiogram ; Informed consent receive protocol treatment : Cognitive communication skill adequate comply study and/or followup procedure ; Geographic proximity ability comply weekly study visit duration treatment ; No reproductive potential : If premenopausal Negative serum pregnancy test within 3 day prior initiation protocolbased treatment patient agree use contraceptive method ( abstinence , intrauterine device , barrier device spermicide surgical sterilization ) 3 month completion protocol treatment ; If postmenopausal Amenorrhea ≥ 12 month follicle stimulate hormone ( FSH ) within post menopausal range . Pregnant breast feeding . Prior treatment Abraxane® carboplatin . Prior chemotherapy metastatic breast cancer . Known hypersensitivity component study drug . Active infection . Current neuropathy ≥ grade 2. central nervous system ( CNS ) metastasis determine head CT contrast head MRI . Uncontrolled congestive heart failure ( CHF ) , history myocardial ischemia ( MI ) , unstable angina , stroke , transient ischemia within previous 6 month . Uncontrolled serious contraindicate medical condition illness .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Triple negative</keyword>
</DOC>